Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 233 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR The long road to targeting the holy grail of the immune... November 9, 2020 Glioblastoma Study Highlights Sex Differences in Brain Cancer January 30, 2019 “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... June 8, 2021 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Load more HOT NEWS NICE doesn’t recommend olaparib for patients with certain prostate cancers Time to meet our new chief scientist – Professor KJ Patel Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom...
